The Spring 2019 Group Meeting has concluded. With nearly 1,020 attendees, this was the most highly attended group meeting in recent history. Schedule and Other Resources Here
Congratulations to Roisin M. Connolly, MD (Johns Hopkins University), winner of the 2019 Young Investigator Award
The Journal of Clinical Oncology says “Landmark advances in molecular diagnostics continue, with the most significant achievement in 2018 made as a result of the TAILORx breast cancer study” More Here
TAILORx is among the notable articles of 2018 in The New England Journal of Medicine — one of two cancer advances on the list of 12 More Here
Oncology Times features 2018 Young Investigator Symposium presenters Read Article
First-Line Ibrutinib-Based Rx More Effective, Less Toxic Than Standard for Younger CLL Patients, E1912 Trial Shows Clinical Oncology
E2511 trial finds that adding veliparib to frontline chemotherapy is effective for patients with extensive-stage small-cell lung cancer Journal of Clinical Oncology
E1912 trial results in practice change for CLL patients Read Press Release
Genome Web: ‘Black Women with Breast Cancer Fare Worse’ according to TAILORx data Read Article (requires free registration)
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD